Literature DB >> 23210041

Clinical and angiographic outcomes of wingspan stent placement for treatment of symptomatic intracranial stenosis: single center experience with 19 cases.

Jun Hyoung Lee1, Ji Kwang Yun, Dae Won Kim, Sung Don Kang.   

Abstract

OBJECTIVE: The limitations of medical management of symptomatic intracranial arterial stenosis (ICS) have prompted development of new strategies, including endovascular treatment. However, stenting of symptomatic ICS remains investigational. Here, we have reported and analyzed a series of 19 endovascular procedures involving placement of a Wingspan stent.
METHODS: We conducted a retrospective review of a series of ICS in which patients were treated with percutaneous transarterial balloon angioplasty and stent placement (PTAS). Patients included in the study were diagnosed as symptomatic ICS between May 2010 and September 2011.
RESULTS: Nineteen patients (median age, 65 years; 12 males, seven women) were treated with the Wingspan stent system for symptomatic ICS ranging from 50% to 99%. The technical success rate was 100%. The location of ICS included the internal carotid (n = 5; 1 petrous, 3 cavernous, and 1 clinoid segments), vertebral (n = 1; V4 segment), basilar (n = 1), and middle cerebral (n = 12; 9 M1, 3 M2) arteries. There was no occurrence of procedure-related mortality. Periprocedural morbidity occurred in two cases (10.5%), including carotid-cavernous fistula (n = 1) and subarachnoid hemorrhage (n = 1). No ipsilateral stroke was recorded beyond 30 days during a mean follow-up period of 13.2 months (range 9-19 months). Restenosis (> 50%) was observed in one patient (6.3%), who was asymptomatic, on follow-up imaging.
CONCLUSION: Wingspan stent for symptomatic ICS can be performed with a high rate of technical success and acceptable periprocedural morbidity rates. Our initial experience indicates that this procedure represents a viable treatment option for this patient population.

Entities:  

Keywords:  Angioplasty; Intracranial stenosis; Stent implantation; Wingspan stent

Year:  2012        PMID: 23210041      PMCID: PMC3491208          DOI: 10.7461/jcen.2012.14.3.157

Source DB:  PubMed          Journal:  J Cerebrovasc Endovasc Neurosurg        ISSN: 2234-8565


  23 in total

1.  Percutaneous transluminal angioplasty of intracranial artery stenosis: clinical results in 24 patients.

Authors:  E Berg-Dammer; H Henkes; W Weber; P Berlit; D Kuhne
Journal:  Neurosurg Focus       Date:  1998-10-15       Impact factor: 4.047

2.  Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN STEMI trial.

Authors:  Jung-Sun Kim; Jaedeok Kim; Donghoon Choi; Chan Joo Lee; Sang Hak Lee; Young-Guk Ko; Myeong-Ki Hong; Byoung-Keuk Kim; Seong Jin Oh; Dong Woon Jeon; Joo-Young Yang; Jung Rae Cho; Nam-Ho Lee; Yun-Hyeong Cho; Deok-Kyu Cho; Yangsoo Jang
Journal:  JACC Cardiovasc Interv       Date:  2010-03       Impact factor: 11.195

3.  Race and sex differences in the distribution of cerebral atherosclerosis.

Authors:  R J Wityk; D Lehman; M Klag; J Coresh; H Ahn; B Litt
Journal:  Stroke       Date:  1996-11       Impact factor: 7.914

4.  Randomized comparison of coronary stent implantation and balloon angioplasty in the treatment of de novo coronary artery lesions (START): a four-year follow-up.

Authors:  A Betriu; M Masotti; A Serra; J Alonso; F Fernández-Avilés; F Gimeno; T Colman; J Zueco; J L Delcan; E García; J Calabuig
Journal:  J Am Coll Cardiol       Date:  1999-11-01       Impact factor: 24.094

5.  US multicenter experience with the wingspan stent system for the treatment of intracranial atheromatous disease: periprocedural results.

Authors:  David Fiorella; Elad I Levy; Aquilla S Turk; Felipe C Albuquerque; David B Niemann; Beverly Aagaard-Kienitz; Ricardo A Hanel; Henry Woo; Peter A Rasmussen; L Nelson Hopkins; Thomas J Masaryk; Cameron G McDougall
Journal:  Stroke       Date:  2007-02-08       Impact factor: 7.914

6.  Stenting of Symptomatic Atherosclerotic Lesions in the Vertebral or Intracranial Arteries (SSYLVIA): study results.

Authors: 
Journal:  Stroke       Date:  2004-04-22       Impact factor: 7.914

7.  Durability of endovascular therapy for symptomatic intracranial atherosclerosis.

Authors:  Mikael Mazighi; Jay S Yadav; Alex Abou-Chebl
Journal:  Stroke       Date:  2008-04-17       Impact factor: 7.914

8.  Angioplasty for symptomatic intracranial stenosis: clinical outcome.

Authors:  Michael P Marks; Joan C Wojak; Firas Al-Ali; Mahesh Jayaraman; Mary L Marcellus; John J Connors; Huy M Do
Journal:  Stroke       Date:  2006-02-23       Impact factor: 7.914

9.  Race-ethnicity and determinants of intracranial atherosclerotic cerebral infarction. The Northern Manhattan Stroke Study.

Authors:  R L Sacco; D E Kargman; Q Gu; M C Zamanillo
Journal:  Stroke       Date:  1995-01       Impact factor: 7.914

10.  Prognosis of patients with symptomatic vertebral or basilar artery stenosis. The Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) Study Group.

Authors: 
Journal:  Stroke       Date:  1998-07       Impact factor: 7.914

View more
  3 in total

1.  Undersized angioplasty and stenting of symptomatic intracranial tight stenosis with Enterprise: Evaluation of clinical and vascular outcome.

Authors:  Kun-Yu Lee; David Yen-Ting Chen; Hui-Ling Hsu; Chi-Jen Chen; Ying-Chi Tseng
Journal:  Interv Neuroradiol       Date:  2015-11-04       Impact factor: 1.610

2.  Ocular ischemic syndrome due to severe internal carotid artery stenosis improved by intracranial stent placement: A case report.

Authors:  Wataru Uchida; Tomoya Kamide; Takehiro Uno; Akifumi Yoshikawa; Kouichi Misaki; Mitsutoshi Nakada
Journal:  Surg Neurol Int       Date:  2021-06-21

3.  Comparison of Drug-eluting Coronary Stents, Bare Coronary Stents and Self-expanding Stents in Angioplasty of Middle Cerebral Artery Stenoses.

Authors:  Jong-Hyeog Lee; Sung-Min Jo; Kwang-Deog Jo; Moon-Kyu Kim; Sang-Youl Lee; Seung-Hoon You
Journal:  J Cerebrovasc Endovasc Neurosurg       Date:  2013-06-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.